Brain+ A/S
CSE:BRAINP
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBITDA returns to its Industry Average (15), the stock would be worth kr0.54 (12 773% upside from current price).
| Scenario | EV/EBITDA Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 0.1 | kr0 |
0%
|
| Industry Average | 15 | kr0.54 |
+12 773%
|
| Country Average | 10.3 | kr0.37 |
+8 765%
|
Forward EV/EBITDA
Today’s price vs future ebitda
Peer Comparison
| Market Cap | EV/EBITDA | P/E | ||||
|---|---|---|---|---|---|---|
| DK |
B
|
Brain+ A/S
CSE:BRAINP
|
4.8m DKK | 0.1 | -0.4 | |
| US |
C
|
Cerner Corp
LSE:0R00
|
31.3B USD | 21.9 | 53.1 | |
| US |
|
Veeva Systems Inc
NYSE:VEEV
|
27.7B USD | 21.2 | 30.4 | |
| AU |
|
Pro Medicus Ltd
ASX:PME
|
15.1B AUD | 78 | 63 | |
| JP |
|
M3 Inc
TSE:2413
|
1T JPY | 10.1 | 20.8 | |
| SE |
|
Sectra AB
STO:SECT B
|
51.1B SEK | -131.6 | 95 | |
| US |
W
|
Waystar Holding Corp
NASDAQ:WAY
|
5.1B USD | 15.8 | 44.6 | |
| US |
|
Doximity Inc
NYSE:DOCS
|
4.5B USD | 15 | 18.9 | |
| CN |
|
Winning Health Technology Group Co Ltd
SZSE:300253
|
19.2B CNY | -121.8 | -62.4 | |
| US |
V
|
Vocera Communications Inc
F:V00
|
2.4B EUR | 267.9 | -328 | |
| US |
H
|
Heartflow Inc
NASDAQ:HTFL
|
2.7B USD | 0 | 0 |
Market Distribution
| Min | 0.6 |
| 30th Percentile | 5.1 |
| Median | 10.3 |
| 70th Percentile | 16.4 |
| Max | 10 882.4 |
Other Multiples
Brain+ A/S
Glance View
Brain+ A/S is engaged in the developing of medical software to detect and treat the cognitive symptoms of dementia and the most common cause of dementia, namely Alzheimer's disease. The firm focuses on the development of digital treatment for dementia and Alzheimer’s disease by digital therapeutics. The Company’s main activities include the development of Cognitive Stimulation Therapy for the treatment of dementia, Computerized Cognitive Training for the treatment of earlier stages of Alzheimer’s and Starry Night memory test for early detection and monitoring of Alzheimer’s. The company offers a product called Digital CST assistant giving access to Cognitive Stimulation Therapy sessions, available in Danish.
